<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847938</url>
  </required_header>
  <id_info>
    <org_study_id>CHD066-08</org_study_id>
    <nct_id>NCT00847938</nct_id>
  </id_info>
  <brief_title>Comparision of Different Dose of Neostigmine at Advanced Decurarization</brief_title>
  <acronym>NEODEC</acronym>
  <official_title>Randomized, Controlled, Double-blind, Prospective Study, Comparing Different Doses of Neostigmine at Advanced Decurarization .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromuscular blockers (NMB) are currently used in anesthesia. Residual paralysis (RP) due to
      NMB is responsible for respiratory disorders after extubation. Neuromuscular blockade is
      monitored by train-of-four (TOF) stimulation at the adductor pollicis. To exclude a RP a
      mechanomyographic TOF ratio of 0.9 is mandatory. But mecanomyography is not available in
      clinical routine. Acceleromyography is the most currently monitoring available in daily
      practice but it has been proved that an acceloromyographic (AMG) TOF ratio of 1.0 is
      necessary to exclude a RP. The incidence of RP in recovery room is underestimated. So to
      perform a safe extubation, reversal of the neuromuscular blockade is necessary when an AMG
      TOF ratio has not reached 1.0. Reversal of neuromuscular blockade is achieved with
      neostigmine. The recommended dose is 0.04 mg/kg. The administration of neostigmine causes
      parasympathomimetic effects which has to be reversed with atropine. When neuromuscular
      blockade is light (AMG TOF ratio of 0.4 which corresponds to the absence of fade at the
      visual evaluation of the TOF), a low dose of neostigmine might be sufficient with less side
      effects expected. The goal of the study is to compare the delay between a light neuromuscular
      block and an AMG TOF ratio of 1.0 for three neostigmine regimens of neostigmine 0.04, 0.02,
      0.01 mg/kg with atropine respectively 0.02, 0.01, 0.005 mg/kg and a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mesure of the Train-of-four (TOF)</measure>
    <time_frame>from neostigmine injection to TOF ratio = 0.9 and 1.0, evaluated every minute up to 1 hour</time_frame>
    <description>train-of-four monitoring (also known as neuromuscular monitoring), is a technique used during recovery from the application of general anesthesia to objectively determine how well a patient's muscles are able to function, by recording muscle response after nerves electrical stimulation.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no injection of neostigmine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>0.04 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>0.02 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>0.01 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient &gt; 18 years

          -  informed consent signed

          -  Patient undergoing any type of scheduled surgery under general anesthesia for which
             curarization with eventually a maintenance is indicated

          -  ASA score between I to III

        Exclusion Criteria:

          -  patient &gt; 75 years and &lt; 18 years

          -  body mass index &gt; 32 mg/m²

          -  neurology disease, neuromuscular or muscular disease

          -  peripheral neuropathy

          -  coronary heart disease

          -  asthma

          -  familial history of malign hyperthermia

          -  difficulty of intubation and ventilation

          -  full stomach

          -  known or suspected allergy to one of the study drug

          -  mecanique obstruction of digestive or urinary tract

          -  open-angle glaucoma

          -  patient with risk of urinary retention linked to urethra-prostatic disorder

          -  concomittant medication with a influence known on neuromuscular (aminosid,
             anti-convulsif and corticosteroid

          -  child bearing women or nursing mother

          -  no affiliation at a social security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florent Capron, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD Vendee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <results_first_submitted>June 14, 2018</results_first_submitted>
  <results_first_submitted_qc>May 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2019</results_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neostigmine</keyword>
  <keyword>neuromuscular blocking agent</keyword>
  <keyword>train of four</keyword>
  <keyword>anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neostigmine 40 µg/kg</title>
          <description>neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
neostigmine: 0.04 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="P2">
          <title>Neostigmine 20 µg/kg</title>
          <description>neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
neostigmine: 0.02 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="P3">
          <title>Neostigmine 10 µg/kg</title>
          <description>neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
neostigmine: 0.01 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>no injection of neostigmine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neostigmine 40 µg/kg</title>
          <description>neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
neostigmine: 0.04 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="B2">
          <title>Neostigmine 20 µg/kg</title>
          <description>neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
neostigmine: 0.02 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="B3">
          <title>Neostigmine 10 µg/kg</title>
          <description>neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
neostigmine: 0.01 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>no injection of neostigmine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="17.6"/>
                    <measurement group_id="B2" value="51.9" spread="18.1"/>
                    <measurement group_id="B3" value="60.2" spread="11.4"/>
                    <measurement group_id="B4" value="50.6" spread="14.8"/>
                    <measurement group_id="B5" value="53.3" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="3.6"/>
                    <measurement group_id="B2" value="25.4" spread="3.7"/>
                    <measurement group_id="B3" value="26.9" spread="4.0"/>
                    <measurement group_id="B4" value="26.9" spread="3.3"/>
                    <measurement group_id="B5" value="25.7" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Physical Status Classification System</title>
          <description>ASA I A normal healthy patient ASA II A patient with mild systemic disease ASA III A patient with severe systemic disease ASA IV A patient with severe systemic disease that is a constant threat to life ASA V A moribund patient who is not expected to survive without the operation ASA VI A declared brain-dead patient whose organs are being removed for donor purposes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ASA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>surgery time</title>
          <units>minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.2" spread="40.4"/>
                    <measurement group_id="B2" value="75.8" spread="32.4"/>
                    <measurement group_id="B3" value="84.1" spread="54.9"/>
                    <measurement group_id="B4" value="78.1" spread="44.3"/>
                    <measurement group_id="B5" value="79.6" spread="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mesure of the Train-of-four (TOF)</title>
        <description>train-of-four monitoring (also known as neuromuscular monitoring), is a technique used during recovery from the application of general anesthesia to objectively determine how well a patient's muscles are able to function, by recording muscle response after nerves electrical stimulation.</description>
        <time_frame>from neostigmine injection to TOF ratio = 0.9 and 1.0, evaluated every minute up to 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neostigmine 40 µg/kg</title>
            <description>neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
neostigmine: 0.04 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
          </group>
          <group group_id="O2">
            <title>Neostigmine 20 µg/kg</title>
            <description>neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
neostigmine: 0.02 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
          </group>
          <group group_id="O3">
            <title>Neostigmine 10 µg/kg</title>
            <description>neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
neostigmine: 0.01 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>no injection of neostigmine</description>
          </group>
        </group_list>
        <measure>
          <title>Mesure of the Train-of-four (TOF)</title>
          <description>train-of-four monitoring (also known as neuromuscular monitoring), is a technique used during recovery from the application of general anesthesia to objectively determine how well a patient's muscles are able to function, by recording muscle response after nerves electrical stimulation.</description>
          <units>minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>recovery time to TOF ratio of 0.9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.3" upper_limit="7"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.5" upper_limit="8"/>
                    <measurement group_id="O3" value="11.5" lower_limit="3.8" upper_limit="17.5"/>
                    <measurement group_id="O4" value="19" lower_limit="10.5" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>recovery time to TOF ratio of 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O2" value="7.8" lower_limit="3.5" upper_limit="11"/>
                    <measurement group_id="O3" value="17" lower_limit="7" upper_limit="55"/>
                    <measurement group_id="O4" value="26" lower_limit="20" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Neostigmine 40 µg/kg</title>
          <description>neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
neostigmine: 0.04 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="E2">
          <title>Neostigmine 20 µg/kg</title>
          <description>neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
neostigmine: 0.02 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="E3">
          <title>Neostigmine 10 µg/kg</title>
          <description>neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
neostigmine: 0.01 mg/kg IV bolus, injection when the of train of four is &gt; or = to 40 %</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>no injection of neostigmine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Florent CAPRON</name_or_title>
      <organization>Clinique Jules Verne</organization>
      <phone>0251171775 ext 33</phone>
      <email>florent.capron@mla.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

